Citi Reiterates “Buy” Rating on Bristol Myers Squibb; Cash Flow Looking Good (BMY)

Pharmaceuticals maker Bristol Myers Squibb Co. (BMY) on Friday caught some continued bullish support from analysts at Citigroup.

The firm maintained its “Buy” rating and $40 price target on BMY, which suggests a 15% upside to the stock’s Thursday closing price of $34.79.

A Citigroup analyst commented, “We model ’15E-’20E EPS growth for BMY of ~16% supported by added risk-adj sales for BMY’s anti-PD-1 antibody in oncology & our maintained risk-adj. sales est’s. for, BMY’s hepatitis C franchise & best-in-class blood thinner Eliquis. Our PT is supported by a DCF value of $44/share.”

Bristol Myers Squibb shares were mostly flat in premarket trading Friday.

The Bottom Line
We have been recommending shares of Bristol Myers Squibb (BMY) since Aug.25, 2009, when the stock was trading at $22.58. The company has a 3.91% dividend yield, based on last night’s closing stock price of $34.79.

Bristol Myers Squibb Co. (BMY) is a “Recommended” dividend stock, holding a DARS™ Rating of 3.5 out of 5 stars.

Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.

Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here